drug-repurposing

Drug repurposing candidates are ranked by integrating target-based and phenotype-based methodologies with evidence from DGIdb, OpenTargets, ChEMBL, and DrugBank to ensure high-confidence therapeutic recommendations based on mechanistic relevance and translatability.

Systematic drug repurposing evaluates candidates using a rigorous evidence hierarchy ranging from Mendelian randomization to computational predictions, ranking compounds by mechanistic relevance, translatability, and evidence tier strength.

Validating drug-target interactions requires a mechanism-of-action audit that checks pathway relevance and directionality against multi-source database evidence to ensure biological plausibility before clinical development.

Clinical translatability assessment screens approved drug candidates for safety, PK/PD feasibility, and regulatory or IP viability before committing to development for new therapeutic indications.

Evaluating candidates for idiopathic pulmonary fibrosis involves analyzing target-disease associations and ranking them by evidence strength to prevent the pursuit of scientifically weak or clinically untranslatable compounds.

Cross-referencing DGIdb and OpenTargets data ensures systematic integration of target-based and phenotype-based methodologies, providing multi-source evidence required to generate high-confidence therapeutic recommendations.